Brief: BioXcel Therapeutics Submits Supplemental NDA To US FDA For IGALMI® At-Home Label Expansion
20/01/2026 12:17
Jan 20 (Reuters) - BioXcel Therapeutics Inc BTAI.O: BIOXCEL THERAPEUTICS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR IGALMI® LABEL EXPANSION IN THE AT-HOME SETTING BIOXCEL THERAPEUTICS INC: SUBMISSION TIMELINE SUPPORTS POTENTIAL APPROVAL OF IGALMI LABEL EXPANSION AS EARLY AS YEAR-END 2026 Source text: ID:nGNX9RVZfy Further company coverage: BTAI.O (Reporting by Kunal Das) ((Kunal.Das2@thomsonreuters.com;))
Recent news on BioXcel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna
Brief: Bioxcel Therapeutics Enters Into Asset Sale Agreement With Teva Pharmaceuticals
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna, Ulta Beauty